New research suggests that how people metabolize nicotine differently may hold the answer to finding out which smoking cessation product will work best for each patient, Medical News Today reports. The study was joint research project between four different universities.
The research was conducted at:
- Perelman School of Medicine at the University of Pennsylvania in Philadelphia
- Centre for Addiction and Health at the University of Toronto, Canada
- State University of New York at Buffalo, New York
- The University of Texas MD Anderson Cancer Center in Houston
Each participant was given 11 weeks of treatment with behavioral therapy, but the kind of treatment each participant received was random. Participants were assessed at the end of the 11-week period, then again at 6 and 12 months.
Participants were treated with either:
- The nicotine patch plus a placebo pill.
- Varenicline plus placebo patch.
- Placebo patch and pill.
"Matching a treatment choice based on the rate at which smokers metabolize nicotine could be a viable strategy to help guide choices for smokers and ultimately improve quit rates,” says lead author Caryn Lerman, PhD, professor of psychiatry and director of Penn Medicine's Center for Interdisciplinary Research on Nicotine Addiction. “These findings not only support the use of the nicotine metabolite ratio as a biomarker to guide treatment choices, but also underscore the notion that tobacco dependence is a heterogeneous condition and that smoking cessation treatments are not equally effective for all smokers."
The findings were published in The Lancet Respiratory Medicine.